Champions Oncology Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $56.27 million
- Book Value:
- Revenue TTM:
- $53.68 million
- Operating Margin TTM:
- Gross Profit TTM:
- $25.48 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Champions Oncology Inc had its IPO on 2003-01-10 under the ticker symbol CSBR.
The company operates in the Healthcare sector and Biotechnology industry. Champions Oncology Inc has a staff strength of 230 employees.
Shares of Champions Oncology Inc opened at $4.21 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $4.21 - $4.27, and closed at $4.27.
This is a +2.89% increase from the previous day's closing price.
A total volume of 3,611 shares were traded at the close of the day’s session.
In the last one week, shares of Champions Oncology Inc have increased by +6.75%.
Champions Oncology Inc's Key Ratios
Champions Oncology Inc has a market cap of $56.27 million, indicating a price to book ratio of 9.8273 and a price to sales ratio of 1.3785.
In the last 12-months Champions Oncology Inc’s revenue was $53.68 million with a gross profit of $25.48 million and an EBITDA of $-815000. The EBITDA ratio measures Champions Oncology Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Champions Oncology Inc’s operating margin was -5.68% while its return on assets stood at -5.46% with a return of equity of -38.26%.
In Q0.33333333333333, Champions Oncology Inc’s quarterly earnings growth was a negative -28.6% while revenue growth was a negative 3.2%.
Champions Oncology Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.24 per share while it has a forward price to earnings multiple of 43.4783 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Champions Oncology Inc’s profitability.
Champions Oncology Inc stock is trading at a EV to sales ratio of 1.7334 and a EV to EBITDA ratio of 38.2905. Its price to sales ratio in the trailing 12-months stood at 1.3785.
Champions Oncology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- Total Liabilities
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Champions Oncology Inc ended 2023 with $36151.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $36151.00 while shareholder equity stood at $7064.00.
Champions Oncology Inc ended 2023 with $0 in deferred long-term liabilities, $20797.00 in other current liabilities, 14.00 in common stock, $-72301018.44 in retained earnings and $335.00 in goodwill. Its cash balance stood at $11645.00 and cash and short-term investments were $11645.00. The company’s total short-term debt was $1,166 while long-term debt stood at $0.
Champions Oncology Inc’s total current assets stands at $20359.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $8053.00 compared to accounts payable of $4298.00 and inventory worth $0.
In 2023, Champions Oncology Inc's operating cash flow was $-754000.00 while its capital expenditure stood at $754000.
Comparatively, Champions Oncology Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Champions Oncology Inc stock is currently trading at $4.27 per share. It touched a 52-week high of $9.88 and a 52-week low of $9.88. Analysts tracking the stock have a 12-month average target price of $9.5.
Its 50-day moving average was $4.29 and 200-day moving average was $6.57 The short ratio stood at 5.35 indicating a short percent outstanding of 0%.
Around 2396.4% of the company’s stock are held by insiders while 7115.7% are held by institutions.
Frequently Asked Questions About Champions Oncology Inc
Similar Industry Stocks (Biotechnology)
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.